Kurume University Cardio-Renal Oncology Registry
Not Applicable
- Conditions
- Hematopoietic malignancy, breast cancer
- Registration Number
- JPRN-UMIN000024278
- Lead Sponsor
- Kurume University
- Brief Summary
Over a median 716-day follow-up, CVR-CVT occurred in 24.3%, 15.8%, 38.1%, and 18.0% of leukemia, malignant lymphoma, multiple myeloma, and breast cancer patients respectively. High or very high-risk patients, identified by HFA-ICOS, had significantly more CVR-CVT events. The 1-year survival rates were 81.2%, 85.8%, 71.1%, and 91.7% for each respective cancer, with CV death in only 0.8% (four patients).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 533
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients as deemed appropriate for participation in this trial by medical doctors
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) New Grade2-4 cardiac disorder (cardiomyopathy, ischemic heart disease, arrhythmia and others) and vascular disorder (thromboembolic event) in CTCAE v4.0-JCOG 2) Progression of renal damage (requiring dialysis and doubling of serum creatinine)
- Secondary Outcome Measures
Name Time Method